申请人:Pfizer Inc.
公开号:US04377581A1
公开(公告)日:1983-03-22
2,4-Diaminoquinazolines of the formula ##STR1## wherein Y.sup.1 is hydrogen or chloro, Y.sup.2 is OR, Y.sup.3 is hydrogen or OR such than when Y.sup.1 is hydrogen, Y.sup.3 is OR and when Y.sup.1 is chloro, Y.sup.3 is hydrogen or OR, and the pharmaceutically acceptable salts thereof; R represents an alkyl group having from one to three carbon atoms; taken separately, R.sup.1 and R.sup.2 are each hydrogen, alkyl having from one to five carbon atoms, cycloalkyl having from three to eight carbon atoms, alkenyl or alkynyl each having from three to five carbon atoms or hydroxy substituted alkyl having from two to five carbon atoms, when taken together with the nitrogen atom to which they are attached R.sup.1 and R.sup.2 form a substituted or unsubstituted heterocyclic group optionally containing an atom of oxygen, sulfur or a second atom of nitrogen as a ring member; their use as antihypertensive agents, pharmaceutical compositions containing them and intermediates for their production.
该专利描述了式子##STR1##中Y.sup.1是氢或氯,Y.sup.2是OR,Y.sup.3是氢或OR,当Y.sup.1是氢时,Y.sup.3是OR,当Y.sup.1是氯时,Y.sup.3是氢或OR。其中R代表一个由一个到三个碳原子组成的烷基;R.sup.1和R.sup.2分别为氢、由一个到五个碳原子组成的烷基、由三到八个碳原子组成的环烷基、由三到五个碳原子组成的烯基或炔基或在有机取代的情况下,为由两个到五个碳原子组成的羟基取代的烷基。当它们与它们所连接的氮原子一起取代时,R.sup.1和R.sup.2形成一个取代或未取代的杂环基,该杂环基可以选择性地包含一个氧原子、硫原子或第二个氮原子作为环成员。该专利还涉及这些化合物作为降压剂的用途,包含它们的制药组合物以及它们的中间体的生产。